Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent
1980-02-10
1982-09-21
Naff, David M.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
435 68, 435240, 435241, 260112R, A61K 3702, C07G 700, C12N 500, C12P 2100
Patent
active
043506879
ABSTRACT:
A purified cell growth factor is produced which comprises a substantially purified glycoproteinaceous factor from platelets which has mitogenic activity toward transformed cells, a molecular weight of 3,000-5,000 daltons and a pI of 7.8-8.3. The growth factor is stable to treatment with 4M guanidine hydrochloride, and is heat labile when treated at 100.degree. C. for 5 minutes.
REFERENCES:
patent: 4261976 (1981-04-01), Isselbacher et al.
patent: 4269825 (1981-05-01), Bohn et al.
Kohler et al. Experimental Cell Research 87 (1974) pp. 297-301.
Kepner et al., Platelets As A Source of Cell-Proliferating Activity Platelets, Raven (1978) 205-212.
Kepner Nancy
Lipton Allan
McCowin Kathleen S.
Naff David M.
Research Corporation
LandOfFree
Platelet derived cell growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platelet derived cell growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platelet derived cell growth factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2076251